Two-Pronged attack: new drug combo aims to shrink tumors before esophageal cancer surgery
NCT ID NCT07493993
Summary
This study is testing whether a new two-drug immunotherapy (iparomlimab and tuvonralimab) combined with a chemotherapy drug (nab-paclitaxel) can help shrink tumors before surgery for people with a type of esophageal cancer. The goal is to see if this 'neoadjuvant' treatment makes surgery more effective by killing more cancer cells beforehand. Researchers will measure how many patients have no cancer cells left after surgery and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.